Drug firm Alembic Pharmaceuticals on Friday said it has received tentative approval from the US health regulator for Bimatoprost Ophthalmic Solution, indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
The approved product is therapeutically equivalent to the reference listed drug product Lumigan ophthalmic solution 0.01 per cent, of Allergan Inc.
The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Bimatoprost Ophthalmic Solution 0.01 per cent, Alembic Pharmaceuticals said in a BSE filing.
Quoting IQVIA sales data, the company said, Bimatoprost Ophthalmic Solution has an estimated market size of USD 704 million for 12 months, ending December 2018.
The company said it now has a total of 100 ANDA approvals from the USFDA.
Shares of Alembic Pharmaceuticals were trading 0.91 per cent higher at Rs 534.75 apiece on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app